Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

Newsletters
Nov 2026
Litigation Update | October 2026
Scientifically Impossible Claims – Not Indefinite, But Not Enabled Douglas B. Wentzel The Federal Circuit held that scientifically impossible-to-perform claims were not indefinite but were invalid for lack of enablement....
Publications
Oct 2026
In Law360 Article, Sean Murray and Jeremiah Helm Explore Unanswered Questions in Federal Circuit Patent Marking Decision
In their latest Law360 column examining noteworthy IP decisions at the Federal Circuit, Knobbe Martens partners Sean Murray and Jeremiah Helm discuss VDPP LLC v. Volkswagen Group of America Inc....
Blogs
Aug 2026
The Problem with Defining the “Problem”: Federal Circuit Affirms Flexible Analogous-Art Analysis
NIELSEN COMPANY (US), LLC v. TVISION INSIGHTS, INC. Before Dyk, Reyna, and Bissoon (Chief District Judge for U.S. District Court for the Western District of Pennsylvania, sitting by designation).  Appeal...